Key facts
- Nammi Therapeutics’s last known valuation is $75.0M.
- It has raised $66.5M; the latest was Later Stage VC ($30.0M) in Jul 2024.
- Notable investors include California Institute for Regenerative Medicine, Magnify, Myeloma Investment Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Nammi Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nammi Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nammi Therapeutics
Operator of an immunotherapy company intended to provide improved treatment of cancer. The company combines immune-modulating prodrugs into lipid nanoparticles for selective delivery to tumors as well as to fight cancer without the serious side effects associated with chemotherapy, enabling patients to receive efficient treatment and recover at a faster speed
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2018
- Employees
- 8
- Website
- nammirx.com/
- Ownership
- Privately Held (backing)
Nammi Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nammi Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nammi Therapeutics in its N-PORT filings yet. We sweep new filings monthly.